Author

Weihua Tang

Institution: X4 Pharmaceuticals, Inc. (United States)

Observed institution: X4 Pharmaceuticals, Inc. (United States)

OpenAlex ID: A5083181533

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

2021 · David C. Dale, Steven P. Treon, et al. · Blood · 4

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

2021 · David C. Dale, Laia Alsina, et al. · Blood · 3

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

2021 · David C. Dale, Frank Caleb Firkin, et al. · Blood · 3

Works count: 3

Citation count: 10

H-index: 3

I10-index: